We aim to bring rapid diagnosis to the point of care by developing diagnostic imaging technologies using advanced optics. Our product is a novel imager that produces high-resolution, 3D digital pathology images of biopsied or surgically-removed tissue specimens at the point of care. Our initial target market will be Mohs surgery, where skin cancers are treated through micrographic excision, and where the Mohs surgeon is also qualified to examine the histopathological image and make a pathological determination. SurgiVance’s device aims to enable rapid surgical margin assessment, reducing procedure time dramatically and improving the overall patient experience. SurgiVance’s patented software solution for digitally coloring or “staining” reflectance confocal images will be available for researchers in life sciences, dermatology, pathology, oncology, and related fields, moving investigators away from glass slides and conventional H&E staining to a faster, more cost effective digital method. Once our imager is validated in Mohs surgery suites, SurgiVance plans to pursue approvals allowing use of its imager for surgical margin assessment of other cancers, and potentially for primary diagnosis of skin and other cancers. Uncharted potential of AI: SurgiVance is AI on 3D confocal pathology, which offers uncharted volumetric analysis advantages over standard AI pathology. Transformation at scale: SurgiVance has a device patent on a uniquely translational "pathology lab-in-a-box" that can be manufactured inexpensively, small and ruggedly to outfit pathology labs worldwide and create new pathology services in markets that can't support pathology lab infrastructure. Scaling Impact: once we have a hundred thousand devices out there imaging millions of cancers in 3D, the network effect will make it no longer about seeing one tumor through one microscope but seeing the disease its self, as a global team and getting the intelligence to stop it.